Yangzhou Medline Industry Co., Ltd. (hereinafter called "MEDLINE") ,authorized by State Food and Drug Administration, is a state-recognized professional manufacturer of disposable sterile medical appliances. Located in the beautiful and historical city Yangzhou, it is quite near Shanghai and Nanjing .

 

MEDLINE is a national high-tech enterprise dedicated to the production, sales, and research of high-end safe injection consumables. It has passed the EU CE, ISO, US FDA, and South Korean KGMP certifications, and has registration certificates for multiple domestic CFDA products. We have over 50 invention patents, international patents, and design patents. Our main products include high-end medical consumables such as Safety Injection Series,  Safety Infusion and Blood Collection Series，Disposable Medical Protective Mask，etc. We mainly export to the United States, Brazil, Italy, Germany, South Korea, Taiwan, and other regions.

 

MEDLINE has currently reached strategic distribution agreements with domestic pharmaceutical giants such as Sinopharm Group, and is fully expanding its domestic market through Sinopharm channels. The core product vaccine safety needle currently has the largest export capacity in China and is establishing a global vaccine syringe production base. The safety injection needle has been rated as a specialized, refined, and new product in Jiangsu Province. The company has won honors such as Jiangsu Province's science and technology oriented small and medium-sized enterprise, Yangzhou City's "Green Yang Golden Phoenix Talent" and district level innovative talent, Jiangsu Province's small giant enterprise, and the top ten innovative enterprise platforms in the Economic Development Zone.

 

With the change of the international market, MEDLINE has begun the development in the domestic markets on the basis of export. Meanwhile, MEDLINE will go on implementing strategy of "markets development, products innovation", developing more products with high-tech and values for high-profile customers in the world, and sparing no efforts for the development of MEDLINE and favor of patients.